CC Y-NC 4. Licence É Copyright 224 EM É October 224 É Oncology 25 stressed. However, work is still needed to identify which patients with dMMR EC might not benefit ...
Pernicious Anaemia: Mechanisms, Diagnosis, and Management
Jan 24, 2020 · INTRODUCTION. Pernicious anaemia (PA) (also known as Biermer’s disease 1 and Addisonian anaemia 2) is a macrocytic anaemia caused by a vitamin B12 (cobalamin) deficiency, which, in turn, is the result of intrinsic factor (IF) deficiency.IF is a glycoprotein that binds cobalamin and thereby enables its absorption at the terminal ileum. 3 Whether the stomach pathogen Helicobacter pylori plays ...
- [PDF]
Abstract Highlights
The following highlights showcase late-breaking research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024.
EMJ | Elevating the quality of healthcare globally
This week, Jonathan is joined by David Gómez-Almaguer, Head of the Haematology Service at University Hospital Monterrey, Mexico. They discuss advancements in stem cell transplantation, the state of haematology in Latin America, and the future of innovative therapies in the field.
82% (95% CI: 75–89) Pembro+CP N=92 Odds ratio for response with Pembro+CP: 1.83 (95% CI: 0.92–3.66) Odds ratio for response with Pembro+CP: 1.74 (95% CI: 1.18–2.58)
May 2, 2024 · Abbreviations: AML: acute myeloid leukemia; CCUS: clonal cytopenia of undetermined significance; del: deletion; EB: excess blasts; FISH: fluorescence in situ ...
Why EGFR Exon 21 L858R Mutations Should Be Treated Differently
BACKGROUND. EGFR gene mutations have been reported in 15–60% of non-small cell lung cancers (NSCLCs) with an important difference in prevalence between Eastern and Western populations. 1,2 The most common EGFR-activating mutations in NSCLC include in-frame deletions in exon 19 and a substitution in exon 21 (L858R) which account for 47% and 41%, respectively, of observed EGFR mutations in ...
30 EM Ø September 2024 Ø Copyright 2024 EM Ø CC BY-NC 4.0 Licence Clinical Practice Insights for Hyperpigmentation Treatment Interview Summary Hyperpigmentation ...
Oct 4, 2024 · 2 Factor XI/XIa Inhibitors: What We Now Know Interview Interview Summary The emerging class of agents targeting factor XI/XIa offers the paradigm-
Interactive Content - European Medical Journal
Oct 31, 2024 · This interactive article summarises key discussions from GSK sponsored symposia that took place during the ESCMID Global Congress 2024, held from 27–30th April 2024 in Barcelona, Spain.